November 16, 2020
Astellas shares its community newsletter for the Duchenne community including an update on its Phase 1b Study: a study to assess the safety, tolerability and preliminary efficacy of ASP0367 (MA0211) in pediatric male participants with Duchenne muscular dystrophy (DMD). Click here to read the full newsletter.
Join Jett Foundation for a virtual presentation and live Q&A with Astellas on Wednesday, November 18, 2020 at 2:00PM ET. Register now!
Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org
Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*)Â
Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!
Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.
